A Medical Device Daily
Haemonetics (Braintree, Massachusetts) reported that it has acquired Neoteric Technology (Vancouver, British Columbia).
Neoteric markets a full end-to-end suite of products to track, allocate, release, and dispense hospital blood units, while controlling inventory and recording the disposition of blood.
The acquisition is expected to be neutral to earnings for Haemonetics in the first year and accretive thereafter. Terms of the deal were not disclosed.
Neoteric's products include the BloodTrack suite of solutions which extend control of blood products from the hospital blood bank through to the transfusion to the patient. "Smart" refrigerators located in operating suites, emergency rooms, and other parts of the hospital dispense blood units with just-in-time control and automated tracking.
Brian Concannon, Haemonetics' president/CEO, said, "We are pleased to be adding the Neoteric product offering to Haemonetics' blood management solutions portfolio, which currently includes devices, software applications, and consulting services. These solutions will enable us to deliver a more complete blood management solution to the hospital market. The Neoteric blood tracking system reduces costs while improving patient care and optimizing blood management practice."
Geof Auchinleck, president of Neoteric, said, "We are pleased to be joining Haemonetics and providing a valuable solution which perfectly complements Haemonetics' portfolio for improving blood management throughout the entire blood supply continuum. Through our integration into Haemonetics, we gain a global marketing reach for our system which can provide simpler, safer blood transfusions for millions of patients worldwide."
Neoteric's products will be integrated into Haemonetics' patient division for marketing and sales. The company's operations will remain in Vancouver and the UK. The BloodTrack suite of products are 510(k) and European-regulatory cleared for sales.
Concannon added, "With the acquisition of Neoteric Technology for hospital blood management and the March acquisition of Altivation Software for blood banks, Haemonetics continues to strengthen its value proposition to customers. Both acquisitions are strategic and strengthen our vision of being the global leader in blood management solutions for our customers."
In other dealmaking news, PPD (Wilmington, Delaware) said it has completed the acquisition of AbCRO, expanding its operations in Central and Eastern Europe.
The acquisition strengthens PPD's ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client base in the Balkans and surrounding countries.
PPD is one of the largest CROs operating in this high-growth region that offers efficient access to patients, a well-developed, centralized healthcare system and low density of clinical trials.
"Eastern Europe is a strong, emerging area for clinical research," said Fred Eshelman, CEO of PPD. "AbCRO's reputation as a premier CRO in this region builds upon our ability to conduct global trials in an area we continue to target for expansion."